Free Newsletter
Chinese outsourcing poses new risks
What's the biggest risk of relying on Chinese drug manufacturers? Ask any five people on the street, and you'd likely get "contamination" as your answer five times. But experts are increasingly worried that China's explosive growth in drug and active-ingredient manufacturing presents a national-security risk.
Yes, a national security risk. Here's a scenario: Say there's an anthrax attack in the U.S., and thousands of people need antibiotics to either treat or prevent the disease. The active ingredients for anthrax treatments are only made in China and India now. Indeed, chemicals for a host of meds are churned out in China daily. If China and Taiwan had a conflict, would the U.S. still be able to get those active ingredients? "The whole drug supply could be in jeopardy in these kinds of situations," one market-watcher theorized.
That market-watcher happens to be president of a chemicals manufacturing trade group, so he has a particular interest in wooing active ingredient manufacturing back to the West. Still, as reliance on Chinese drug and chemicals makers continues to grow--just think of all the drug makers pledging to outsource more of their manufacturing--it's a point to ponder.
- read the article from the Kansas City Star
Related Articles:
China pushes drug development as R&D soars. Report
Overseas drugmaking goes unsupervised. Report
Drug-safety hazards many and growing. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: